TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15013587

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (RT) with concurrent carboplatin/vindesine followed by surgery (arm A)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional RT followed by surgery (arm B)
Number of subjects: 126
Study: 11602814

Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9840854

Group type: EXPERIMENTAL
Intervention: 25 mg tramadol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg metoclopramide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5 mL normal saline
Number of subjects: 10
Study: 8077826

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous injection of local anaesthetic beneath the cuff
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard axillary block anaesthesia
Number of subjects: 40
Study: 2683281

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) - intravenous infusion of 1.5 million International Units during one hour
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA) - 160 mg daily for 30 days
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Combination of SK and ASA
Number of subjects: 17187

Group type: COMPARATOR
Intervention: Placebo treatment only
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 17187
Study: 335572

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (MSP) 1, 3, 5, 10, 20, 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MSS) 1, 3, 5, 10, 20, 30 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle or sterile saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSP and MSS (equal doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSP 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSP 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSS 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSP 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSP and MSS (equivalent doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSP and MSS
Number of subjects: 0
Study: 30978155

Group type: EXPERIMENTAL
Intervention: Intermittent PEG-Asparaginase (3 doses at 6-week intervals)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Continuous PEG-Asparaginase (10 doses at 2-week intervals)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Intermittent PEG-Asparaginase
Number of subjects: 625

Group type: COMPARATOR
Intervention: Continuous PEG-Asparaginase
Number of subjects: 625
Study: 28549923

Group type: EXPERIMENTAL
Intervention: Consistently sufficient vitamin D group (25(OH)D >50 nmol/L at months 3 and 24)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Fluctuating vitamin D group (25(OH)D >50 nmol/L at either point)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Consistently insufficient vitamin D group (serum 25(OH)D ≤50 nmol/L at months 3 and 24)
Number of subjects: 413
Study: 25538270

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 23799454

Group type: EXPERIMENTAL
Intervention: Early feeding (4th hour after PEG placement)
Number of subjects: 69
Study: 21892006

Group type: EXPERIMENTAL
Intervention: HB-AS02
Number of subjects: 151

Group type: COMPARATOR
Intervention: HB-AS04
Number of subjects: 151
Study: 19352339

Group type: EXPERIMENTAL
Intervention: Continuous adalimumab 40 mg every other week (e.o.w.)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Continuous adalimumab 40 mg every week
Number of subjects: 778

Group type: COMPARATOR
Intervention: Induction dosing followed by reinitiation of adalimumab
Number of subjects: 778
Study: 17873301

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life improvement
Number of subjects: 0
Study: 15226773

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (NI) - intensive, individualised nutrition counselling by a dietitian using a standard protocol and oral supplements if required
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (UC) - general advice and nutrition booklet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (NI)
Number of subjects: 60
Study: 11851743

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9591224

Group type: COMPARATOR
Intervention: tolcapone 200 mg with immediate-release levodopa/carbidopa formulations
Number of subjects: 30

Group type: COMPARATOR
Intervention: tolcapone 200 mg with controlled-release levodopa/carbidopa formulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: tolcapone 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 7908624

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 MU thrice weekly) for one year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 60
Study: 2892388

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Oxprenolol and non-beta-blocker treatment
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 537

Group type: COMPARATOR
Intervention: Beta-blocker-based therapy
Number of subjects: 537
Study: 31750855

Group type: EXPERIMENTAL
Intervention: Marine ω‐3 fatty acid, 1 g daily (including eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg)
Number of subjects: 25871

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 25871

Group type: EXPERIMENTAL
Intervention: Marine ω‐3 fatty acid, 1 g daily
Number of subjects: 25871
Study: 31752864

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm using artificial neural network (TensorFlow) trained on multi-center neuropsychological test data
Number of subjects: 14926
Study: 28738895

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (sham manipulation)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (continued usual but non‐manual management)
Number of subjects: 19
Study: 25843054

Group type: EXPERIMENTAL
Intervention: Low dose (1% THC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Medium dose (4% THC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High dose (7% THC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23658394

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal capsular polysaccharide, CRM197 conjugate vaccine (PCV7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 0
Study: 21237188

Group type: EXPERIMENTAL
Intervention: 12 mg of lutein and 1 mg of zeaxanthin daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 19686995

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) preparation (90 mL in divided doses)
Number of subjects: 276

Group type: COMPARATOR
Intervention: High-dose bisacodyl preparation (6 tablets of 5mg bisacodyl) plus water lavage (2 L of water)
Number of subjects: 276
Study: 17876336

Group type: EXPERIMENTAL
Intervention: EGFR-positive tumours
Number of subjects: 54

Group type: COMPARATOR
Intervention: EGFR-negative tumours
Number of subjects: 54
Study: 15032409

Group type: EXPERIMENTAL
Intervention: Survcard (Group I)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional diagnostic methods (Group II)
Number of subjects: 58
Study: 11277449

Group type: EXPERIMENTAL
Intervention: Signal detection paradigm with audio signals
Number of subjects: 55
Study: 9530159

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 80 mg/kg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Aqueous 5% glucose (control)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Graft liver (no DCA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control liver (no DCA)
Number of subjects: 49
Study: 8067224

Group type: EXPERIMENTAL
Intervention: Super Safety Yellow
Number of subjects: 200

Group type: COMPARATOR
Intervention: Super Safety Clear
Number of subjects: 200

Group type: COMPARATOR
Intervention: PVC-tubes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Women
Number of subjects: 200

Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 200
Study: 2499527

Group type: EXPERIMENTAL
Intervention: CHPP‐M (continuous hyperthermic peritoneal perfusion with mitomycin C)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no CHPP‐M treatment)
Number of subjects: 82
Study: 4881070

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suramin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melarsonyl potassium (Mel W)
Number of subjects: 0
Study: 31272488

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 480

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 480
Study: 28862513

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs) at baseline
Number of subjects: 819

Group type: COMPARATOR
Intervention: No glucocorticoids (GCs) at baseline
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoids (highest tertile)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoids (lowest tertile)
Number of subjects: 819
Study: 26507607

Group type: EXPERIMENTAL
Intervention: Intervention A (nutrition education for children)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intervention B (education for teachers)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 212
Study: 23732262

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 61
Study: 21707127

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study: 20592050

Group type: EXPERIMENTAL
Intervention: Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Health professionals' involvement in the trial
Number of subjects: 45
Study: 18320867

Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day plus esterified conjugated estrogens 0.312 mg/day
Number of subjects: 14
Study: 16252374

Group type: EXPERIMENTAL
Intervention: Snoezelen intervention implemented in 24-hour care with a 4-day in-house training program and follow-up activities.
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care in control wards.
Number of subjects: 129
Study: 12009719

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 155
Study: 10352372

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7594334

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg q.d. (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Famotidine 20 mg b.i.d. (n = 10)
Number of subjects: 20
Study: 2179066

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg after evening meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg before evening meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg with snacks allowed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg with snacks forbidden
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with snacks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo without snacks
Number of subjects: 0
Study: 6783419

Group type: EXPERIMENTAL
Intervention: Cholestyramine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High cholesterol diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects vs. patients heterozygous for familial hypercholesterolaemia
Number of subjects: 0
Study: 31526892

Group type: EXPERIMENTAL
Intervention: VSP 5
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: VSP 7
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: VSP 2
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: VSP 6
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: VSP 4
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Manual diameter measurements
Number of subjects: 156
Study: 28438283

Group type: EXPERIMENTAL
Intervention: Music stimulation (n = 204)
Number of subjects: 409

Group type: COMPARATOR
Intervention: No music (n = 205)
Number of subjects: 409
Study: 25567841

Group type: EXPERIMENTAL
Intervention: 40% of the standard dose of IPV intradermally
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: 20% of the standard dose intradermally
Number of subjects: 231

Group type: COMPARATOR
Intervention: full standard dose intramuscularly
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: 40% of the standard dose intramuscularly
Number of subjects: 231
Study: 23212720

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin
Number of subjects: 14264

Group type: EXPERIMENTAL
Intervention: R(2)CHADS(2) model including creatinine clearance
Number of subjects: 14264

Group type: EXPERIMENTAL
Intervention: R(2)CHADS(2) model validated in external population
Number of subjects: 14264
Study: 21887214

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (A/L)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: atovaquone-proguanil (A/P)
Number of subjects: 19
Study: 19454737

Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 464000

Group type: EXPERIMENTAL
Intervention: Other blood pressure lowering drugs
Number of subjects: 464000

Group type: EXPERIMENTAL
Intervention: Blood pressure reduction of 10 mm Hg systolic or 5 mm Hg diastolic
Number of subjects: 464000

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 464000

Group type: EXPERIMENTAL
Intervention: Three drugs at half standard dose
Number of subjects: 464000

Group type: EXPERIMENTAL
Intervention: Other blood pressure lowering drugs (excluding non-cardioselective β blockers)
Number of subjects: 464000
Study: 17574482

Group type: EXPERIMENTAL
Intervention: Group A: 5 ml of 5% NaOCl + 2.5 ml of 3.6% H(2)O(2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group B: 5 ml of 5% NaOCl + 2.5 ml of 17% ethylenediamine tetraacetic acid
Number of subjects: 40
Study: 15043765

Group type: EXPERIMENTAL
Intervention: New-generation antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, sertindole, amisulpride, aripiprazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New-generation antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study: 11703949

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at <2 hours
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at >=2 hours
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at 2 to <4 hours
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at 4 to <6 hours
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at >6 hours
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with later reperfusion
Number of subjects: 1232
Study: 9628595

Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection
Number of subjects: 556

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 556

Group type: COMPARATOR
Intervention: Watchful waiting (crossover to surgery)
Number of subjects: 556
Study: 7829035

Group type: EXPERIMENTAL
Intervention: Home hospice care for patients living alone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular hospice care
Number of subjects: 34
Study: 3121836

Group type: EXPERIMENTAL
Intervention: 24 h infusion of phosphate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 24 h infusion of calcium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not infused phosphate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not infused calcium
Number of subjects: 14
Study: 29659754

Group type: EXPERIMENTAL
Intervention: Standard of care plus oseltamivir initiated within 24 hours of enrollment (group B)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Standard of care (group A)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Standard of care plus oseltamivir (group B)
Number of subjects: 1107
Study: 27070386

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 25391865

Group type: EXPERIMENTAL
Intervention: Group A: 120 kVp with 350 mgI/ml iodinated contrast agent
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group B: 100 kVp with 350 mgI/ml iodinated contrast agent
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group C: 100 kVp with 270 mgI/ml iodinated contrast agent
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 45
Study: 23868011

Group type: EXPERIMENTAL
Intervention: Anastrozole (3 additional years of treatment)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Nil (no additional treatment)
Number of subjects: 634
Study: 16015270

Group type: EXPERIMENTAL
Intervention: Butter (40 g daily for 4 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cheese (40 g daily for 4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Run-in period (less saturated fat)
Number of subjects: 19
Study: 11849857

Group type: EXPERIMENTAL
Intervention: Primary Angioplasty (PA)
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Age >70
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Anterior location
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Treatment >2 h after symptoms onset
Number of subjects: 1375
Study: 10366082

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 228

Group type: COMPARATOR
Intervention: Pilocarpine 4%
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1% (long-term use)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% (long-term use)
Number of subjects: 228
Study: 7741336

Group type: EXPERIMENTAL
Intervention: Tornalate (38% ethanol)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bronkometer (30% ethanol)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alupent (0% ethanol)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Blood ethanol levels
Number of subjects: 3
Study: 1665182

Group type: EXPERIMENTAL
Intervention: Lisinopril-hydrochlorothiazide (L/HCTZ)
Number of subjects: 286
Study: 6109543

Group type: EXPERIMENTAL
Intervention: Aggro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30063558

Group type: EXPERIMENTAL
Intervention: Foveal-sparing ILM peeling (FS group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Complete ILM peeling (CP group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 28651150

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) for 4 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 33
Study: 25881049

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfuse if haemoglobin concentration <7.5 g/dl)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfuse if haemoglobin concentration <9 g/dl)
Number of subjects: 2000
Study: 24018463

Group type: EXPERIMENTAL
Intervention: S-PD (metal-ceramic screwed partial dentures)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: S-CD (metal-ceramic screwed complete dentures)
Number of subjects: 131

Group type: COMPARATOR
Intervention: HP (fixed-detachable hybrid prostheses)
Number of subjects: 131
Study: 21518684

Group type: EXPERIMENTAL
Intervention: HemCon pad
Number of subjects: 136

Group type: COMPARATOR
Intervention: Regular pad
Number of subjects: 136
Study: 18053055

Group type: EXPERIMENTAL
Intervention: CryoHist
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cryocup
Number of subjects: 75

Group type: COMPARATOR
Intervention: Miami Special
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CryoHist (for large specimens >2.5 cm)
Number of subjects: 75
Study: 17042886

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day) with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 82
Study: 12776851

Group type: EXPERIMENTAL
Intervention: Parent ratings
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adolescent self-ratings
Number of subjects: 60
Study: 10902861

Group type: EXPERIMENTAL
Intervention: Ferric trimaltol (four different pharmaceutical formulations)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal colorimetry
Number of subjects: 12